# Risk Assessment & Mitigation Plan
## Closed-Loop Diabetes Management System

**Document Version:** 1.0
**Date:** 2025-11-23
**Status:** Draft
**ISO 14971 Compliant:** Yes

---

## Table of Contents
1. [Risk Management Overview](#1-risk-management-overview)
2. [Clinical & Safety Risks](#2-clinical--safety-risks)
3. [Technical Risks](#3-technical-risks)
4. [Regulatory Risks](#4-regulatory-risks)
5. [Business Risks](#5-business-risks)
6. [Operational Risks](#6-operational-risks)
7. [Risk Monitoring & Review](#7-risk-monitoring--review)

---

## 1. Risk Management Overview

### 1.1 Risk Management Framework (ISO 14971)

**Process:**
```
1. Risk Analysis
   ├─ Intended Use & Characteristics
   ├─ Hazard Identification
   └─ Risk Estimation (Severity × Probability)

2. Risk Evaluation
   └─ Compare to Acceptability Criteria

3. Risk Control
   ├─ Inherent Safety by Design
   ├─ Protective Measures
   └─ Information for Safety

4. Residual Risk Evaluation
   └─ Benefit-Risk Analysis

5. Risk Management Review
   └─ Production & Post-Production Information
```

### 1.2 Risk Acceptability Criteria

**Risk Matrix:**

| Severity ↓ / Probability → | Frequent (>10%) | Probable (1-10%) | Occasional (0.1-1%) | Remote (<0.1%) |
|----------------------------|-----------------|------------------|---------------------|----------------|
| **Catastrophic (Death)** | Unacceptable | Unacceptable | Unacceptable | ALARP* |
| **Critical (Serious Injury)** | Unacceptable | Unacceptable | ALARP* | Acceptable |
| **Serious (Injury)** | Unacceptable | ALARP* | Acceptable | Acceptable |
| **Minor (Discomfort)** | ALARP* | Acceptable | Acceptable | Acceptable |
| **Negligible (No harm)** | Acceptable | Acceptable | Acceptable | Acceptable |

*ALARP = As Low As Reasonably Practicable (requires risk reduction and benefit-risk justification)

### 1.3 Risk Management Team

- Chief Medical Officer (Chair)
- VP Engineering
- VP Regulatory Affairs
- Quality Assurance Lead
- Clinical Affairs Lead
- Security Officer

---

## 2. Clinical & Safety Risks

### 2.1 Hypoglycemia Risks

#### Risk 2.1.1: Severe Hypoglycemia from Insulin Over-Delivery

**Hazard:** Algorithm commands excessive insulin delivery

**Severity:** Catastrophic (can cause death)
**Probability before mitigation:** Occasional (0.5%)
**Initial Risk Level:** Unacceptable

**Causes:**
1. Software bug in insulin dosing algorithm
2. Incorrect glucose reading from CGM
3. User input error (carbs logged incorrectly)
4. Sensor signal interference

**Mitigations:**
1. **Inherent Safety:**
   - Maximum insulin delivery limits (hard-coded)
   - Conservative algorithm defaults
   - IOB (insulin on board) tracking and limits
   - Predictive low glucose suspend (PLGS)

2. **Protective Measures:**
   - Multiple safety checks:
     - Mobile app validates command
     - Backend validates command
     - Pump validates command
   - User confirmation for large boluses (>5U)
   - Automatic basal rate reduction when glucose trending low
   - Alert user before predicted hypoglycemia (30 min advance)

3. **Information for Safety:**
   - User training on system operation
   - Clear labeling about hypoglycemia risk
   - Symptoms of hypoglycemia education
   - Emergency procedures (glucose tablets, glucagon)

**Verification:**
- Extensive testing with UVA/Padova simulator
- Clinical trial safety monitoring (zero severe events)
- Algorithm validation (>10,000 simulated scenarios)

**Residual Risk:**
- **Severity:** Catastrophic
- **Probability after mitigation:** Remote (<0.01%)
- **Residual Risk Level:** ALARP (acceptable with benefit-risk justification)

**Benefit-Risk Justification:**
- Benefit: Significant improvement in glycemic control (TIR +10-15%)
- Benefit: Reduced burden of diabetes management
- Benefit: Improved quality of life
- Risk: Residual hypoglycemia risk <0.01% with severe harm
- **Conclusion:** Benefits outweigh residual risks

---

#### Risk 2.1.2: Hypoglycemia from Exercise Not Detected

**Hazard:** System doesn't reduce insulin during exercise

**Severity:** Critical (serious injury)
**Probability:** Probable (5%)
**Risk Level:** Unacceptable

**Mitigations:**
1. Exercise logging feature (user indicates exercise)
2. Activity detection (if wearable integrated)
3. Algorithm detects rapid glucose drop pattern
4. User education on pre-exercise carbs
5. Automatic basal reduction when glucose trending down

**Residual Risk:** Acceptable (with user training)

---

### 2.2 Hyperglycemia Risks

#### Risk 2.2.1: Prolonged Hyperglycemia from Under-Dosing

**Hazard:** Algorithm delivers insufficient insulin

**Severity:** Serious (can lead to DKA if prolonged)
**Probability:** Occasional (1%)
**Risk Level:** ALARP

**Causes:**
1. Conservative algorithm (intentionally err on side of safety)
2. Pump occlusion (insulin not delivered)
3. Infusion site failure
4. Insulin degradation (expired or heat-exposed)

**Mitigations:**
1. Pump occlusion detection (pressure sensors)
2. Alert user if glucose >250 mg/dL for >2 hours
3. Alert user if glucose not responding to insulin
4. Ketone monitoring (if available)
5. User education on sick day management

**Residual Risk:** Acceptable

---

#### Risk 2.2.2: Diabetic Ketoacidosis (DKA)

**Hazard:** Severe insulin deficiency leads to DKA

**Severity:** Catastrophic (can cause death)
**Probability:** Remote (0.05%)
**Risk Level:** ALARP

**Causes:**
1. Pump failure (no insulin delivered for hours)
2. Severe illness
3. Infusion site failure

**Mitigations:**
1. Pump status monitoring (reservoir, battery, occlusion)
2. Alert if no insulin delivered for >1 hour
3. Alert if glucose >300 mg/dL
4. Educate on DKA symptoms (nausea, vomiting, rapid breathing)
5. Recommend backup insulin (MDI)

**Residual Risk:** ALARP (acceptable with education and monitoring)

---

### 2.3 Device Failure Risks

#### Risk 2.3.1: Complete System Failure

**Hazard:** All components fail simultaneously

**Severity:** Critical
**Probability:** Remote (0.1%)
**Risk Level:** ALARP

**Causes:**
1. Mobile app crash
2. Backend service outage
3. CGM sensor failure
4. Pump failure

**Mitigations:**
1. **Graceful Degradation:**
   - If mobile app fails: Pump continues last basal rate
   - If backend fails: Mobile app operates in offline mode
   - If CGM fails: System suspends automated insulin (alerts user)
   - If pump fails: Alert user immediately

2. **Redundancy:**
   - Offline mode (mobile app stores data locally)
   - Fail-safe mode (revert to pre-programmed basal rates)
   - Multiple alerts (app, SMS, email)

3. **User Education:**
   - Always have backup insulin (pens/vials)
   - Know your pre-programmed basal rates
   - Manual pump operation training

**Residual Risk:** Acceptable

---

### 2.4 User Error Risks

#### Risk 2.4.1: Incorrect Carbohydrate Entry

**Hazard:** User logs wrong carb amount, leading to incorrect bolus

**Severity:** Serious
**Probability:** Probable (10%)
**Risk Level:** ALARP

**Mitigations:**
1. Carb database with common foods
2. Confirmation prompt for large carb entries (>100g)
3. Machine learning suggests carb amounts based on meal photos
4. User can cancel/edit bolus for 5 minutes after delivery starts
5. Safety limits prevent excessive bolus even if carbs wrong

**Residual Risk:** Acceptable

---

## 3. Technical Risks

### 3.1 Software Risks

#### Risk 3.1.1: Software Bug Causing Incorrect Insulin Dose

**Severity:** Catastrophic
**Probability before mitigation:** Occasional (1%)
**Risk Level:** Unacceptable

**Mitigations:**
1. **Development Practices:**
   - IEC 62304 compliance (medical device software)
   - Code reviews (2+ reviewers)
   - Static analysis (linting, type checking)
   - Unit tests (>90% coverage)
   - Integration tests
   - End-to-end tests

2. **Testing:**
   - Automated regression testing (every commit)
   - Manual QA testing
   - Simulation testing (UVA/Padova simulator: 10,000+ scenarios)
   - Clinical validation

3. **Safety Constraints:**
   - Multiple layers of validation
   - Safety limits hard-coded (cannot be changed by algorithm)
   - Watchdog timers

4. **Change Control:**
   - All software changes reviewed and approved
   - Risk assessment for each change
   - Regression testing

**Residual Risk:** ALARP

---

#### Risk 3.1.2: ML Model Prediction Error

**Severity:** Serious
**Probability:** Probable (5%)
**Risk Level:** Unacceptable initially

**Mitigations:**
1. **Model Validation:**
   - Validate on hold-out test set (RMSE <20 mg/dL)
   - Continuous monitoring in production
   - A/B testing before full deployment

2. **Conservative Algorithms:**
   - ML predictions inform, but classical control decides
   - Safety layer (MPC) always active
   - ML can suggest, but cannot override safety limits

3. **Confidence Intervals:**
   - Report prediction uncertainty
   - If low confidence, use more conservative approach

4. **Fallback:**
   - If ML model fails or performs poorly, revert to classical control
   - Automatic rollback if error rate increases

**Residual Risk:** Acceptable

---

### 3.2 Cybersecurity Risks

#### Risk 3.2.1: Unauthorized Access to System

**Severity:** Critical (could modify insulin commands)
**Probability:** Occasional (0.5%)
**Risk Level:** Unacceptable

**Mitigations:**
See Security & Privacy Plan (Document 06) for full details.

**Summary:**
1. Multi-factor authentication
2. End-to-end encryption
3. Certificate pinning
4. Intrusion detection
5. Regular security audits
6. Penetration testing

**Residual Risk:** ALARP

---

#### Risk 3.2.2: Data Breach (Patient Privacy)

**Severity:** Serious (HIPAA violation)
**Probability:** Occasional (0.5%)
**Risk Level:** ALARP

**Mitigations:**
1. Encryption at rest and in transit
2. Access controls (RBAC)
3. Audit logging
4. Security awareness training
5. Incident response plan

**Residual Risk:** Acceptable

---

### 3.3 Device Communication Risks

#### Risk 3.3.1: Bluetooth Connection Loss

**Severity:** Serious (loss of closed-loop)
**Probability:** Probable (5%)
**Risk Level:** ALARP

**Causes:**
1. Distance between phone and devices
2. Bluetooth interference
3. Low battery on phone or devices

**Mitigations:**
1. **Automatic Reconnection:**
   - Attempt reconnection every 30 seconds
   - Alert user if disconnected >5 minutes

2. **Fail-Safe Mode:**
   - Pump continues last basal rate
   - User manually monitors glucose

3. **User Alerts:**
   - Immediate notification of connection loss
   - Instructions for reconnection

**Residual Risk:** Acceptable

---

#### Risk 3.3.2: CGM Signal Interference

**Severity:** Critical (incorrect glucose reading)
**Probability:** Occasional (1%)
**Risk Level:** ALARP

**Causes:**
1. Electromagnetic interference (MRI, electrical devices)
2. Sensor signal loss
3. Sensor inaccuracy

**Mitigations:**
1. **Data Validation:**
   - Reject physiologically impossible values (<40 or >400 mg/dL)
   - Reject rapid changes (>5 mg/dL per minute)
   - Require 3 consecutive readings before acting

2. **User Alerts:**
   - Alert if CGM signal lost
   - Alert if values seem inaccurate
   - Recommend finger stick confirmation

3. **Fail-Safe:**
   - If CGM unreliable, suspend automated insulin delivery
   - Revert to manual mode

**Residual Risk:** Acceptable

---

## 4. Regulatory Risks

### 4.1 FDA Approval Risks

#### Risk 4.1.1: FDA Does Not Approve PMA

**Severity:** Critical (cannot launch)
**Probability:** Occasional (10%)
**Impact:** Very High (business failure)

**Causes:**
1. Clinical trial endpoints not met
2. Safety concerns
3. Inadequate documentation
4. Unproven algorithm efficacy

**Mitigations:**
1. **Early Engagement:**
   - Pre-Submission (Q-Sub) meeting with FDA
   - Align on trial design and endpoints
   - Regular communication during trial

2. **Conservative Trial Design:**
   - Well-defined endpoints (TIR)
   - Large sample size (240+ participants)
   - Longer follow-up (6 months)
   - Rigorous safety monitoring

3. **Regulatory Expertise:**
   - Hire experienced regulatory consultants
   - Engage FDA law firm
   - Learn from predicate devices

4. **Plan B:**
   - If not approved, conduct additional study
   - Consider De Novo pathway if novel

**Residual Risk:** Medium probability, Very High impact

---

#### Risk 4.1.2: Delayed FDA Approval

**Severity:** Serious (delayed launch)
**Probability:** Probable (30%)
**Impact:** High (cash burn, competitive disadvantage)

**Causes:**
1. FDA requests additional information
2. Advisory panel required (adds 6+ months)
3. Manufacturing questions

**Mitigations:**
1. Build extra time into timeline (18 months for review, not 12)
2. Respond quickly to FDA questions (<30 days)
3. Prepare comprehensive PMA package upfront
4. Secure additional funding (Series C) to sustain operations

**Residual Risk:** Medium

---

### 4.2 Post-Market Surveillance Risks

#### Risk 4.2.1: Reportable Adverse Event Post-Launch

**Severity:** Critical (could lead to recall)
**Probability:** Probable (30% in first year)
**Impact:** High

**Mitigations:**
1. Robust post-market surveillance system
2. Investigate all adverse events within 5 days
3. File MDR reports on time (30 days)
4. Proactive field safety corrective actions
5. Transparent communication with FDA

**Residual Risk:** Acceptable (part of medical device lifecycle)

---

## 5. Business Risks

### 5.1 Market Risks

#### Risk 5.1.1: Low User Adoption

**Severity:** Critical (business failure)
**Probability:** Occasional (20%)
**Impact:** Very High

**Causes:**
1. Users don't trust automated insulin delivery
2. Existing solutions "good enough"
3. High cost / poor insurance coverage
4. Difficult onboarding

**Mitigations:**
1. **Clinical Evidence:**
   - Publish trial results in top journals
   - Present at ADA, EASD conferences
   - Patient testimonials

2. **Pricing:**
   - Work with insurers for coverage
   - Competitive pricing ($100/month or less)
   - Free trial period

3. **User Experience:**
   - Excellent onboarding (30 min or less)
   - 24/7 customer support
   - Simple, intuitive UI

4. **Education:**
   - Partner with diabetes educators
   - Online resources, videos
   - Community building

**Residual Risk:** Medium

---

#### Risk 5.1.2: Competitor Launches First

**Severity:** Serious (market share loss)
**Probability:** Probable (40%)
**Impact:** High

**Competitors:**
- Medtronic 780G (already on market)
- Tandem Control-IQ (already on market)
- Insulet Omnipod 5 (already on market)
- New entrants (Beta Bionics, Diabeloop)

**Mitigations:**
1. **Differentiation:**
   - Superior algorithm (ML-based, personalized)
   - Better user experience
   - Broader device compatibility
   - Lower cost

2. **Speed:**
   - Aggressive timeline
   - Parallel regulatory pathways (US + EU)

3. **Partnerships:**
   - Partner with device manufacturers (Dexcom, Omnipod)
   - Strategic alliances

**Residual Risk:** Medium (competitive market)

---

### 5.2 Financial Risks

#### Risk 5.2.1: Inability to Raise Funding

**Severity:** Catastrophic (company shutdown)
**Probability:** Occasional (15%)
**Impact:** Very High

**Mitigations:**
1. **Phased Funding:**
   - Seed: $2-5M (de-risk early)
   - Series A: $10-15M (after Q-Sub)
   - Series B: $20-30M (after feasibility study)
   - Series C: $30-50M (after pivotal trial data)

2. **Milestone-Based:**
   - Raise based on achieving milestones
   - Demonstrate progress to investors

3. **Diverse Investor Base:**
   - VCs, strategic investors, grants (JDRF, NIH)

4. **Plan B:**
   - Consider strategic acquisition if funding difficult
   - Partner with larger med device company

**Residual Risk:** Medium

---

## 6. Operational Risks

### 6.1 Manufacturing Risks

#### Risk 6.1.1: Supply Chain Disruption

**Severity:** Serious (cannot deliver product)
**Probability:** Occasional (10%)
**Impact:** High

**Mitigations:**
1. Dual sourcing for critical components
2. Safety stock (3 months inventory)
3. Diversified contract manufacturers
4. Long-term supply agreements

**Residual Risk:** Acceptable

---

### 6.2 Team Risks

#### Risk 6.2.1: Loss of Key Personnel

**Severity:** Critical (slowed development)
**Probability:** Occasional (20% over 4 years)
**Impact:** High

**Mitigations:**
1. Competitive compensation (salary + equity)
2. Positive culture and mission-driven work
3. Knowledge documentation (reduce bus factor)
4. Succession planning for critical roles
5. Retention bonuses for key milestones

**Residual Risk:** Acceptable

---

## 7. Risk Monitoring & Review

### 7.1 Risk Review Schedule

| Activity | Frequency | Responsible |
|----------|-----------|-------------|
| Risk Management Review | Quarterly | Risk Management Team |
| FMEA Updates | After major changes | Engineering + QA |
| Clinical Risk Review | Monthly during trials | Clinical Affairs + CMO |
| Post-Market Risk Review | Monthly (first year) | QA + Regulatory |
| Annual Risk Report | Annually | Quality Manager |

### 7.2 Risk Metrics to Monitor

**Clinical:**
- Severe hypoglycemic events per 1000 patient-years
- DKA events per 1000 patient-years
- Device-related adverse events
- User-reported issues

**Technical:**
- Software defect density (bugs per 1000 lines of code)
- System uptime (target >99.9%)
- ML model error rate (RMSE)
- Security incidents

**Business:**
- User growth rate
- Churn rate
- Customer satisfaction score
- Time to onboarding

### 7.3 Risk Reporting

**Internal Reporting:**
- Weekly engineering stand-up (technical risks)
- Monthly executive review (all risks)
- Quarterly board reporting (strategic risks)

**External Reporting:**
- FDA (MDR reports, annual reports)
- Notified Body (EU)
- Investors (quarterly updates)

---

## Appendix A: Failure Mode Effects Analysis (FMEA)

### Sample FMEA Entries

| Failure Mode | Potential Effect | Severity | Potential Cause | Occurrence | Detection | RPN | Actions | New RPN |
|--------------|------------------|----------|-----------------|------------|-----------|-----|---------|---------|
| Software calculates wrong insulin dose | Severe hypoglycemia | 10 | Coding error | 3 | 2 | 60 | Code review, extensive testing, safety limits | 20 |
| CGM reads incorrectly | Wrong insulin dose | 8 | Sensor malfunction | 4 | 5 | 160 | Data validation, multiple readings required | 40 |
| Bluetooth disconnects | Loss of closed-loop | 6 | Interference | 6 | 3 | 108 | Auto-reconnect, fail-safe mode | 36 |
| Pump occlusion | No insulin delivered, hyperglycemia | 8 | Kinked tubing | 4 | 2 | 64 | Occlusion detection, alerts | 16 |

**RPN (Risk Priority Number) = Severity × Occurrence × Detection**
- Target: RPN <100 after mitigations
- Critical: RPN >200 requires immediate action

---

## Appendix B: Traceability Matrix

| Risk ID | Hazard | Mitigation | Verification Method | Status |
|---------|--------|------------|---------------------|--------|
| R-2.1.1 | Insulin over-delivery | Safety limits, validation | Simulation testing, clinical trial | Verified |
| R-3.1.1 | Software bug | Code review, testing | Unit tests, integration tests | Ongoing |
| R-3.2.1 | Unauthorized access | MFA, encryption | Penetration testing | Verified |
| R-4.1.1 | FDA non-approval | Early engagement, conservative trial | Regulatory review | Planned |

---

**Document Approval:**
- Chief Medical Officer: _________________
- VP Engineering: _________________
- VP Regulatory Affairs: _________________
- Quality Assurance Lead: _________________

**Change Log:**
| Version | Date | Author | Changes |
|---------|------|--------|---------|
| 1.0 | 2025-11-23 | Initial | First draft |
